Sign in
8-K

Current Report

Viridian Therapeutics, Inc.\DE Filed Acc 0001590750-19-000063

Material agreement · Agreement ended · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events

  • Item 1.01 Entry into a material definitive agreement
  • Item 1.02 Termination of a material definitive agreement
  • Item 2.05 Costs associated with exit or disposal activities
  • Item 5.02 Departure or appointment of directors or officers
  • Item 7.01 Regulation FD disclosure
  • Item 8.01 Other events

From the SEC's structured data for this filing

Loading mgen-201912118k.htm…